Clinical trials: Embryonal Neoplasm
Glioblastoma
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
In prior trials of CMV RNA-pulsed dendritic cell vaccines, there has been a narrow window between surgery and initiation of chemoradiation to enroll patients and perform leukapheresis (to obtain cells needed to generate…
- Trial name
- NCT04963413
- Testing
- Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Metastatic Melanoma
Peptide Vaccinations Plus GM-CT-01 in Melanoma
The purpose of this study is to determine whether the intravenous and/or GM-CT-01 administration can correct Tumor Infiltrating Lymphocytes (TIL) anergy and induce a more efficient and long-lasting anti-tumoral immune response…
- Trial name
- NCT01723813
- Testing
- Tumor specific peptides: MAGE-3.A1 and / or NA17.A2, Galectin-3 inhibitor: GM-CT-01 systemic injections, Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Effect of Drugs, Quality of Life
Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive.
- Conditions
- Effect of Drugs, Quality of Life, Chordoma, Advanced Cancer
- Trial name
- CSSG-03 (NCT04042597)
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Ewing Sarcoma Family of Tumors
Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan
This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated…
- Trial name
- MGMTLiberati (NCT03542097)
- Testing
- MGMT methylation evaluation
- Where
- 5 sites in Italy, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Istituto Ortopedico Rizzoli
Primary Brain Tumor, Glioblastoma
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia.
- Conditions
- Primary Brain Tumor, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- CBT-I in PBT (NCT06439420)
- Testing
- Cognitive Behavioral Therapy for Insomnia
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Virginia Commonwealth University
Neuroendocrine Tumor, Carcinoid Tumor
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00942682
- Testing
- Sorafenib, RAD001
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Patients with malignant melanoma who had undergone surgery will receive adjuvant treatment with high-dose Intron A for one year.
- Trial name
- NCT00723710
- Testing
- Intron A (interferon alfa-2b; SCH 30500)
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Schwannoma, Vestibular
CyberKnife Radiotherapy for the Treatment of Schwannomas
Historically, the management of schwannomas has relied primarily on observation, surgery, or conventional radiotherapy techniques.
- Trial name
- Schwannomas (NCT07801560)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hartmann Oncology Radiotherapy Group, France
Breast Cancer, Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for skin cancer and cancer that is metastatic to the skin.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer
- Trial name
- NCT00023790
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma, Surgery
Neoadjuvant Chemoradiation for Resectable Glioblastoma
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the…
- Conditions
- Glioblastoma, Surgery, High Grade Glioma
- Trial name
- NeoGlio (NCT04209790)
- Testing
- Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Geisinger Clinic
Low Grade Glioma, Glioblastoma Multiforme
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
Background: The blood-brain barrier helps to protect the central nervous system (brain and spinal cord) from harmful toxins, but also prevents potentially useful chemotherapy from reaching brain tumors.
- Conditions
- Low Grade Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01281982
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma Stage III or IV, No Prior Chemotherapy
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
Investigation of the metabolic activity of sorafenib and sorafenib plus dacarbazine on melanoma metastasis in patients with melanoma stage III or IV on the basis of PET/CT, LDH and S-100 evaluation.
- Trial name
- NCT00794235
- Testing
- Sorafenib (Nexavar), Dacarbazine (DTIC)
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University of Zurich
Congenital Melanocytic Nevi, Melanoma, Skin
Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN.
- Conditions
- Congenital Melanocytic Nevi, Melanoma, Skin, Nevi and Melanomas
- Trial name
- NevustoMel (NCT06605417)
- Testing
- Methylomics, RNA sequencing, Spatial transcriptomics
- Where
- 2 sites in France, Spain
- Volunteers
- 100 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Neuroendocrine Tumors
Treatment With SU11248 in Patients With Neuroendocrine Tumors
To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
- Trial name
- NCT00056693
- Testing
- Sunitinib
- Where
- 11 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer
Recurrent Glioblastoma (WHO-Grade IV Glioma)
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior…
- Trial name
- GliAvAx (NCT03291314)
- Testing
- Axitinib, Avelumab
- Where
- Belgium
- Volunteers
- 52 people
- Sponsor
- Universitair Ziekenhuis Brussel
Merkel Cell Carcinoma, Islet Cell Carcinoma
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Trial name
- NCT00003514
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Neuroblastoma
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00082758
- Testing
- hu14.18-Interleukin-2 fusion protein
- Where
- 81 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Children's Oncology Group
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Glioblastoma
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM).
- Trial name
- NCT05781321
- Testing
- Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18
- Where
- 8 sites in United States
- Volunteers
- 170 people
- Sponsor
- Mayo Clinic
NSCLC, Melanoma
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib.
- Trial name
- NCT02279004
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.